FIT Biotech Oy
Company Release January 1, 2016 at 9:00 am EET
Changes in FIT Biotech’s Board of Directors
FIT Biotech’s board members Rabbe Klemets and Tomi Numminen resign from their board membership at their own request as of January 1, 2016.
The members of FIT Biotech’s Board of Directors are Chairman Rabbe Slätis and members Erkki Pekkarinen, Dirk Teuwen and Juha Vapaavuori.
FIT BIOTECH OY
Board of Directors
Further information:
Rabbe Slätis
Chairman of the Board and acting CEO, FIT Biotech Oy
Tel: +358 (0) 40 840 6749
Email: rabbe.slatis@saunalahti.fi
Certified Advisor: Translink Corporate Finance Oy, tel. +358 20 743 2790
FIT Biotech Oy in brief:
FIT Biotech Oy is a biotechnology company established in 1995, focusing on DNA vaccines and gene therapy. The company bases its products on its patented GTU ® (Gene Transport Unit) technology.
Through GTU technology, FIT Biotech develops DNA vaccines in order to both prevent and also treat various diseases. Identified application areas include HIV, tuberculosis (and other infectious diseases) as well as gene therapy (cancer, autoimmune diseases). Other application areas are under development.
FIT Biotech Oy is listed on NASDAQ First North (ticker: FITBIO). More information can be found at www.fitbiotech.com.
DISTRIBUTION:
NASDAQ OMX Helsinki
Principal media
www.fitbiotech.com
HUG#1976346
